Inventor
DASA LIPOVSEK
Inventor
US
Overview
Patents· 23 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C07Kprimary
C07KPeptides27%
A61KPreparations for medical, dental or toiletry purposes25%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations14%
G01NInvestigating or analysing materials by determining their chemical or physical properties14%
C12NMicroorganisms or enzymes12%
C40BCombinatorial chemistry6%
C07BGeneral methods of organic chemistry1%
Y02ATechnologies for adaptation to climate change1%
PatentTitleYear
12,534,511Serum albumin-binding fibronectin type III domains202612,529,165Stabilized fibronectin based scaffold molecules202612,492,238Glypican-3-binding fibronectin based scaffold molecules202512,427,212Nectin-4 binding miniproteins, conjugates and uses thereof202512,247,058Nucleic acids encoding modified FGF-21 polypeptides, vectors and cells containing, and use thereof202512,194,110PD-L1 binding polypeptides for imaging202512,097,241Methods of treating kidney failure, and/or improving or stablizing renal function using modified relaxin polypeptides202412,097,242Treatment of fibrosis, cardiovascular disease and heart failure with modified relaxin polypeptides202411,913,137Methods for the selection of binding proteins202411,858,979Fibronectin based scaffold domain proteins that bind PCSK9202411,813,315Fibronectin based scaffold domain proteins that bind to myostatin202311,524,992Glypican-3-binding fibronectin based scaffold molecules202211,447,538Fibronectin based scaffold proteins202211,434,275Fast-off rate serum albumin binding fibronectin type III domains202211,408,093Fibronectin binding domains with reduced immunogenicity202211,407,815Stabilized fibronectin based scaffold molecules202211,364,281Modified relaxin polypeptides comprising a pharmacokinetic enhancer and pharmaceutical compositions thereof202211,344,639PET imaging with PD-L1 binding polypeptides202211,279,751Fibronectin binding domains with reduced immunogenicity202211,248,031Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides202211,203,630Serum albumin-binding fibronectin type III domains202111,185,570Method of treating cardiovascular disease and heart failure with modified relaxin polypeptides202111,173,219PD-L1 binding polypeptides for imaging2021Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2021–2026Patents assigned to BRISTOL MYERS SQUIBB CO (22)· patent assignee history
2021–2026Based in US· patent location history
2024Patents assigned to BRISTOL MEYERS SQUIBB CO (1)· patent assignee history
2025Patents assigned to AKTIS ONCOLOGY INC (1)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| BRISTOL MYERS SQUIBB CO | 22 | 2021–2026 |
| AKTIS ONCOLOGY INC | 1 | 2025 |
| BRISTOL MEYERS SQUIBB CO | 1 | 2024 |
Locations
| Location | Patents | Span |
|---|---|---|
| US | 23 | 2021–2026 |